Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 3, 1995, Pages 222-228

  Chou, Ting Chao ^a   Otter, Glenys M ^a   Sirotnak, Francis M ^a  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

Breast cancer; Combination treatment; Edatrexate; Taxol; Taxotere

Indexed keywords

DOCETAXEL; EDATREXATE; PACLITAXEL;

ARTICLE; BREAST CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; AMINOPTERIN; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMAN; PACLITAXEL; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0029655264     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00688320     Document Type: Article

References (32)

1. Mechanism of action of taxol
2. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue
3. Taxol stabilizes microtubules in mouse fibroblasts cells
4. Taxol: mechanisms of action and resistance
5. Phase I trial of taxol given as a 3-hour infusion every 21 days
6. Taxol, a new and effective anticancer drug
7. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties of folates and folic acid antagonists in cancer chemotherapy
8. New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models
9. New folate analogs of the 10-deazaaminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice
10. Edatrexate, an antifolate with antitumor activity: a review
11. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaminopterin in adult patients with advanced cancer
12. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage II and IV non-small cell lung cancer
13. Phase II study of 10-ethyl-10-deaza-aminopterin (10-EDAM: CGP 30694) for stage II B or IV non-small cell lung cancer
14. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer
15. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: National Cancer Institute of Canada clinical trials group study
16. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deazaminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models
17. Intracavitary therapy of murine ovarian cancer with Cis-diaminodichloroplatinum (II) and 10-ethyl-10-deaza-aminopterin incorporating systemic leucovorin protection
18. Effective combination therapy of metastatic murine solid tumors with edatrexate and vinca alkaloids, vinblastine, navelbine and vindesine
19. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors
20. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
21. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents
22. The median-effect principle and the combination index for quantitation of synergism and antagonism
23. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro
24. Schedule dependent synergism of edatrexate and cisplatin combination in the A549 lung cancer cell lines as assessed by median effect analysis
25. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide and cisplatinum regimen for nonsmall cell lung cancer
26. Quantitation of synergism and antagonism of two or more drugs by computerized analysis
27. New colorimetric cytotoxicity assay for anticancer-drug screening
28. Single-agent use of taxol (paclitaxel) in breast cancer
29. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer
30. Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer